In a study monitoring the short-term versus long-term effect of genistein treatment in prostate cancer, short term treatment of PC3-M cells (metastatic prostate cancer cells) in vitro over a period of 8 weeks decreased MMP-2 expression whereas long-term treatment up to 2 months increased MMP-2 levels, emphasizing the fact that early phase chemoprevention trails need to be closely monitored for optimal dose administration duration for maximum efficacy (Zhang et al., 2019). Here, MMP2 is linked to prostate cancer.